SHERWIN STEPHEN A 4

What Happened

• Stephen A. Sherwin, a director of Neurocrine Biosciences (NBIX), was granted 2,567 restricted stock units (RSUs) on May 27, 2026. The Form 4 reports an acquisition price of $0.00 (an award/grant), reflecting a compensation award rather than a cash purchase. The filing classifies the grant as a derivative security (RSUs convert to shares upon vesting).

Key Details

• Transaction date: 2026-05-27; Form 4 filed: 2026-05-29.
• Amount: 2,567 RSUs; reported acquisition price: $0.00.
• Vesting: RSUs vest in full on May 27, 2027 (Footnote: each RSU equals one share on vesting).
• Transaction code: A = Award/Grant; derivative security (RSU).
• Shares owned after the transaction: not provided in the summary data supplied here.
• Filing timeliness: Form filed two days after the transaction date; no indication in the provided data that it was late.

Context

• RSU grants are a common form of executive/director compensation and represent a right to receive shares in the future once vesting conditions are met; they are not an immediate purchase or sale of shares. This award by itself is a routine compensation event and should not be taken alone as a strong bullish or bearish signal.